|
Forecast Period
|
2024-2028
|
|
Market Size (2022)
|
USD 34.09 Billion
|
|
CAGR (2023-2028)
|
7.71%
|
|
Fastest Growing Segment
|
Hospitals & Clinical Laboratories
|
|
Largest Market
|
North America
|
Market Overview
Global Infectious Disease Testing Market
has valued at USD 23.75 Billion in 2022 and is anticipated to project impressive
growth in the forecast period with a CAGR of 8.1% through 2028. Bacteria,
parasites, viruses, and fungi are the causative agents of infectious diseases.
The identification and characterization of these diseases fall under the domain
of infectious disease diagnostics. Physicians and healthcare professionals
primarily rely on patients' symptoms and physical examinations to detect
infectious infections. Additionally, a range of laboratory tests is conducted
to determine the causative agents, enabling healthcare providers to administer
appropriate medical treatments. Pathogens can be transmitted through direct
contact, water or foodborne routes, aerosolization of infected particles in the
environment, as well as via insects (such as mosquitoes) and ticks.
Individuals with compromised immune
systems are particularly vulnerable to certain infections. This includes those
undergoing cancer treatment or recent organ transplant recipients.
Additionally, individuals who have not been vaccinated against common infectious
diseases, healthcare workers, and those traveling to high-risk areas with
mosquito-borne pathogens like malaria and dengue fever are at increased risk.
Various laboratory tests are employed by doctors to diagnose infectious
disorders.
Key Market Drivers
Increasing
Prevalence of Infectious Diseases
The global infectious disease testing
market is experiencing significant growth due to the increasing prevalence of
infectious diseases worldwide. The persistent emergence and re-emergence of
infectious diseases have heightened the demand for accurate and timely
diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and
antibiotic-resistant bacterial infections have underscored the need for rapid
and efficient testing methods to detect, track, and manage these diseases. Additionally,
the globalization of travel and trade has facilitated the rapid spread of
infectious agents across borders, making early detection and containment
crucial to prevent outbreaks. This has driven up the demand for robust
infectious disease testing infrastructure, including diagnostic assays, testing
equipment, and surveillance systems.
Furthermore, the aging global population
is more susceptible to infectious diseases, particularly due to compromised
immune systems. As a result, there is a heightened focus on early detection and
monitoring of infections in elderly individuals, contributing to market growth.
The rising awareness among healthcare
professionals and the general public about the importance of early diagnosis
and prompt treatment has also fueled demand. Timely infectious disease testing
not only aids in better patient care but also helps in preventing the spread of
diseases within communities. The increasing prevalence of infectious diseases,
coupled with the need for rapid and accurate diagnosis, has led to substantial
growth in the global infectious disease testing market. As infectious disease
threats continue to evolve, the market is expected to further expand, with
ongoing advancements in testing technologies and increased investment in public
health infrastructure playing pivotal roles in addressing these global health
challenges.
Shift
in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing
The global infectious disease testing
market is undergoing a significant transformation due to a shift in focus from
centralized laboratories to decentralized point-of-care testing (POCT). Infectious
diseases can spread quickly, and timely diagnosis is crucial for effective
containment and treatment. Decentralized testing allows healthcare providers to
obtain results within minutes to hours, as opposed to waiting for samples to be
transported to and processed in centralized laboratories, which can take days. Another
significant factor is improved patient access to healthcare. POCT allows
testing to be performed in various settings, including primary care clinics,
emergency rooms, pharmacies, and even at home. This accessibility is
particularly valuable in underserved or remote areas where centralized
laboratories may be less accessible.
Furthermore, the adoption of POCT
reduces the burden on centralized laboratories, which can become overwhelmed
during outbreaks or pandemics. This decentralized approach helps distribute the
testing workload, making it more manageable and efficient for healthcare
systems. The global infectious disease testing market is experiencing
significant growth due to the shift in focus from centralized laboratories to
decentralized point-of-care testing. This transformation is driven by the need
for rapid results, improved patient access to testing, pandemic response
requirements, and technological advancements. As the healthcare industry
continues to embrace POCT, it is likely to play an increasingly critical role
in infectious disease diagnostics and management.
Research
on Infectious Disease Diagnostics
Ongoing research is leading to the
development of more accurate, sensitive, and rapid diagnostic technologies.
Molecular diagnostic techniques, such as PCR and next-generation sequencing,
are continuously evolving, enabling the detection of infectious agents with
high precision. These advancements contribute to the expansion of the market as
healthcare providers seek state-of-the-art diagnostic tools. Research into
infectious disease diagnostics extends to the fields of surveillance and
epidemiology. Advanced diagnostic tools are vital for tracking the prevalence,
transmission, and evolution of pathogens. This research is fundamental for
public health responses, including vaccination campaigns and outbreak control,
thus boosting the market's growth. Research in infectious disease diagnostics
often involves global collaborations among governments, healthcare
organizations, academic institutions, and pharmaceutical companies. These
partnerships accelerate the development and adoption of innovative diagnostic
solutions, further expanding the market's reach.
Research-driven advancements in
infectious disease diagnostics are pivotal in increasing the global infectious
disease testing market. The pursuit of more accurate, efficient, and accessible
diagnostic tools is crucial for early detection, effective treatment, and
public health responses. As research continues to address the evolving
landscape of infectious diseases, we can expect further growth and innovation
in this critical healthcare sector.
Technological
Advancement in Advanced Diagnostic Technologies
Technological advancements have led to
the development of highly sensitive and specific diagnostic assays. Molecular
diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid
sequencing, now offer unparalleled precision in detecting infectious agents.
This increased accuracy ensures reliable and early disease detection, which is
critical for effective treatment and containment. The demand for rapid
infectious disease testing has grown significantly, driven by technological
innovations that enable quick results. Point-of-care testing (POCT) devices and
rapid antigen tests provide results within minutes, allowing for immediate
decision-making in clinical settings, public health emergencies, and
travel-related testing.
Automation in diagnostic laboratories
has improved testing throughput and reduced the risk of errors. High-throughput
automated systems can process a large volume of samples efficiently, making
them essential for large-scale testing during outbreaks or pandemics. Technological
advancements in advanced diagnostic technologies are revolutionizing infectious
disease testing by improving accuracy, speed, and accessibility. These
innovations are not only meeting the current demands of healthcare but also
providing essential tools for responding to emerging infectious threats and
improving patient care globally. As technology continues to evolve, the demand
for advanced infectious disease testing is likely to increase further.
Download Free Sample Report
Key Market Challenges
Inadequate
Reimbursements
Inadequate reimbursements within
healthcare systems can indeed have a negative impact on the demand for global
infectious disease testing. Reimbursements play a critical role in healthcare
economics, affecting both healthcare providers and patients. When reimbursement
rates for infectious disease testing are insufficient, healthcare providers,
including hospitals, clinics, and laboratories, may struggle to cover the costs
associated with testing. This financial strain can lead to reduced investment
in testing infrastructure, limited availability of testing services, and even
closures of diagnostic facilities in underserved areas.
Inadequate reimbursement rates can deter
healthcare providers from offering a comprehensive range of infectious disease
testing services. This may result in reduced access to critical diagnostic
tests, leaving patients with limited options for early disease detection and
management. Lower reimbursement rates can discourage laboratories and
diagnostic companies from investing in research and development to improve
testing accuracy, speed, and accessibility. This can stifle innovation and
hinder the development of more advanced and cost-effective testing solutions. Reduced
access to infectious disease testing due to inadequate reimbursements can
exacerbate healthcare disparities, disproportionately affecting underserved
populations. These disparities can result in delayed diagnoses and poorer
health outcomes in vulnerable communities.
Rising
Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
The rising costs of healthcare present a
significant challenge to the adoption and utilization of novel diagnostic
techniques for infectious diseases, thereby decreasing the demand for global
infectious disease testing. Healthcare systems worldwide are grappling with
increasing costs, including personnel, infrastructure, and medication. The
allocation of budgets for novel diagnostic technologies often competes with
other essential healthcare expenditures, making it difficult to justify the
investment in cutting-edge testing methods.
Many novel diagnostic techniques, such as advanced molecular testing
platforms, require expensive equipment and specialized laboratory
infrastructure. Acquiring, maintaining, and operating this equipment can strain
healthcare budgets, particularly in resource-limited settings. Healthcare costs
can exacerbate economic disparities, with individuals in lower-income brackets
facing greater barriers to accessing advanced infectious disease testing. This
can result in delayed diagnoses and treatment, increasing the risk of disease
transmission.
Key Market Trends
Point-of-Care
Testing (POCT)
POCT devices that offer rapid results
and can be used outside traditional healthcare settings will continue to gain
popularity. They are especially valuable in resource-limited and remote areas. POCT
devices are designed to be user-friendly and portable, making them accessible
even in areas with limited healthcare infrastructure. They can be used in
remote clinics, field hospitals, and rural communities, bringing essential
diagnostic capabilities closer to patients.
In resource-limited and remote areas,
access to centralized laboratories for traditional testing can be challenging.
POCT devices offer the advantage of providing immediate results, allowing
healthcare providers to diagnose and initiate treatment promptly. This is
crucial for managing infectious diseases effectively and preventing their
spread. Rapid results from POCT devices mean that patients do not have to wait
for days or weeks to receive their test results. This helps alleviate anxiety,
enables timely medical decisions, and improves patient satisfaction. POCT
devices often require lower initial investments compared to establishing and
maintaining a fully equipped laboratory. This cost-effectiveness is
particularly valuable for healthcare facilities with limited budgets.
Telemedicine
The expansion of telemedicine and remote
healthcare services will increase the demand for home-based testing kits and
virtual consultations with healthcare providers for infectious disease testing
and monitoring. Telemedicine allows patients to access healthcare from the
comfort of their homes, eliminating the need for travel and reducing wait
times. Home-based testing kits align with this convenience, offering a
streamlined way for patients to self-administer tests without visiting a
healthcare facility. Patients with infectious diseases can benefit from
continuous monitoring of their condition. Home-based testing kits enable
patients to collect samples at various intervals, while virtual consultations
allow healthcare providers to assess results and provide guidance on managing
the disease remotely. During outbreaks or pandemics, minimizing in-person
interactions can help reduce the risk of disease transmission. Telemedicine and
home-based testing allow patients to receive necessary care and diagnostic services
while maintaining physical distancing.
Home-based testing data can be
aggregated and anonymized to contribute to public health surveillance efforts.
Patterns and trends in infectious disease data can help authorities monitor
outbreaks and allocate resources more effectively.
Segmental Insights
Product & Service Insights
The
reagents segment holds the largest market share in infectious disease molecular
diagnostics, driven by the introduction and commercialization of new reagents
and their high adoption rate compared to instruments. The demand for PCR
reagents has led to a significant increase in novel reagent launches. For instance,
in March 2021, PCR Biosystems launched IsoFast Bst Polymerase reagents,
enabling faster testing procedures through sensitive, robust, and rapid
amplification of RNA & DNA.
The instrument segment is expected to experience lucrative growth during
the forecast period. Major players are adopting the strategy of acquiring
companies to expand their portfolio in this segment. For example, in March
2021, Roche announced the acquisition of GenMark Diagnostics, a multiplex
molecular diagnostics company, for USD 1.8 billion. This acquisition aligns
with Roche's infectious disease molecular diagnostics portfolio expansion
strategy, ensuring continuous revenue generation and improved patient care in
the years to come.
End User Insights
The Diagnostic Reference Laboratories segment emerged as the
dominant player in the market for infectious disease molecular diagnostics,
capturing the largest revenue share in 2022. This can be attributed to the high
procedure volumes and extensive market penetration achieved by this segment.
Furthermore, the market for infectious disease molecular diagnostics is
expected to witness significant growth due to the increasing number of
government initiatives aimed at providing various services, including diagnostic
test reimbursements. These proactive measures by the government are anticipated
to further propel the demand for infectious disease molecular diagnostics,
thereby driving the overall market growth.
Download Free Sample Report
Regional Insights
During
the projected period, the Global Infectious Disease Diagnostics Market was
dominated by North America. This can be attributed to factors such as rapid
urbanization, increased investments by healthcare providers in infrastructure
improvement, the need to manage the growing burden of infectious diseases, and
government initiatives to improve accessibility of diagnostic services. Europe
followed closely behind. Furthermore, changing regulatory requirements for
infectious disease testing in the general public contributed to the market's
expansion. Moreover, advancements in technology have facilitated the
integration of previously manual processes, resulting in the establishment of
fully automated systems. As a result, it is anticipated that the Infectious
Disease Diagnostics Market in this region will witness substantial growth.
Recent Developments
- July 2022: F.
Hoffmann-La Roche Ltd has unveiled a novel dual antigen and antibody diagnostic
test for hepatitis C. The groundbreaking Elecsys HCV Duo is among the first
immunoassay tests available commercially, enabling simultaneous and independent
determination of the hepatitis C virus strain from a single human plasma or
serum sample.
- February 2022:
SEEGENE has been granted the CE-IVD mark by the EU regulatory authority for
their Allplex SARS-CoV-2 rapid MDx Assay. This assay is suitable for deployment
in airports, schools, and other large-scale institutions, delivering results in
under 30 minutes.
- In June 2018, Roche Diagnostics and GE Healthcare forged a strategic
agreement to co-develop and market digital clinical decision support solutions.
Key Market Players
- Biomérieux SA
- Abbott Laboratories Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Quidel Corporation
- Trinity Biotech PLC
|
By Product &
Service
|
By Technology
|
By Disease
|
By End User
|
By Region
|
- Assays
- Kits
- Reagents
- Instruments
- Services &
Software
|
- Molecular Diagnostics
- Immunoassay
- Microbiology
- Others
|
- Hepatitis
- Human Papillomavirus
(HPV)
- Human
Immunodeficiency Virus (HIV)
- Tuberculosis (TB)
- Hospital-Acquired
Infections (HAIs)
- Others
|
- Hospital and Clinical
Laboratories
- Diagnostic Reference
Laboratories
- Academic/Research
Institutes
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East &
Africa
|
Report Scope:
In this report, the Global Infectious Disease
Testing Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- Infectious Disease Testing Market, By Product & Service:
o Assays
o Kits
o Reagents
o Instruments
o Services & Software
- Infectious Disease Testing Market, By Technology:
o Molecular Diagnostics
o Immunoassay
o Microbiology
o Others
- Infectious Disease Testing Market, By Disease:
o Hepatitis
o Human Papillomavirus (HPV)
o Human Immunodeficiency
Virus (HIV)
o Tuberculosis (TB)
o Hospital-Acquired
Infections (HAIs)
o Others
- Infectious Disease Testing
Market, By
End User:
o Hospital and Clinical
Laboratories
o Diagnostic Reference
Laboratories
o Academic/Research
Institutes
o Others
- Infectious Disease Testing Market,
By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
§ Turkey
§ Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Infectious Disease Testing Market.
Available Customizations:
Global Infectious Disease Testing market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Infectious Disease Testing Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]